Drug Trial News

RSS
Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Almost half of total funding for publication of clinical trials is not disclosed, finds research

Almost half of total funding for publication of clinical trials is not disclosed, finds research

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

TB Alliance initiates SimpliciTB to test if new four-drug regimen can treat most types of tuberculosis

TB Alliance initiates SimpliciTB to test if new four-drug regimen can treat most types of tuberculosis

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Study demonstrates cardiovascular safety of weight loss drug

Study demonstrates cardiovascular safety of weight loss drug

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

UAB receives NIH grant to continue evaluation of new medication for IPF

UAB receives NIH grant to continue evaluation of new medication for IPF

Researchers complete testing a new drug to treat rheumatoid arthritis

Researchers complete testing a new drug to treat rheumatoid arthritis

Immunotherapy combination shrinks melanoma that has spread to the brain

Immunotherapy combination shrinks melanoma that has spread to the brain

Scientists publish study results of AAV therapy product for treatment of RHO-adRP

Scientists publish study results of AAV therapy product for treatment of RHO-adRP

NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine

NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine

Trial shows PARP inhibitor as novel treatment option for patients with advanced breast cancers

Trial shows PARP inhibitor as novel treatment option for patients with advanced breast cancers

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes

Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

Beat Childhood Cancer consortium's clinical trial offers new hope to children in Canada

Beat Childhood Cancer consortium's clinical trial offers new hope to children in Canada

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.